<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03650400</url>
  </required_header>
  <id_info>
    <org_study_id>CQAW039B2201</org_study_id>
    <nct_id>NCT03650400</nct_id>
  </id_info>
  <brief_title>Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to &lt; 12 Years With Asthma</brief_title>
  <official_title>A Multicenter, Open-label, 8 Day Treatment Study to Assess the Pharmacokinetics, Safety and Tolerability of Fevipiprant Delivered Via a Once Daily Chewable Tablet in Children Aged 6 to &lt;12 Years With Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to assess the pharmacokinetics (PK) of fevipiprant (QAW039)
      delivered as a chewable tablet (CT) in pediatric asthma subjects aged 6 to &lt; 12 years with
      asthma. The results of this study will support the identification of a fevipiprant dose for
      subsequent pediatric efficacy studies aiming to provide an exposure similar to that of the
      to-be marketed adult/adolescent dose. In addition, the first data on safety and tolerability
      of fevipiprant in this age group was obtained.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study was to assess the pharmacokinetics (PK) of fevipiprant delivered as
      a chewable tablet (CT) in pediatric asthma subjects aged 6 to &lt; 12 years. The results of this
      study would have supported the identification of a fevipiprant dose for subsequent pediatric
      efficacy studies aiming to provide an exposure similar to that of the to-be marketed
      adult/adolescent dose. Based on evaluation of the fevipiprant asthma development program in
      the recently completed studies (CQAW039A2307/ CQAW039A2314) in the adult population (the
      analyses of these studies did not meet the clinically relevant threshold for reduction in
      rate of moderate-to-severe exacerbation compared to placebo over a 52-week treatment period
      for either of the doses [i.e. 150 mg/ 450 mg]), Novartis decided to discontinue this study
      (CQAW039B2201).
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Company Decision
  </why_stopped>
  <start_date type="Actual">May 1, 2019</start_date>
  <completion_date type="Actual">January 22, 2020</completion_date>
  <primary_completion_date type="Actual">December 16, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>There will be 2 treatment dose cohorts studied (fevipiprant dose A once daily and one higher dose selected based on PK obtained at dose A mg/day, fevipiprant dose B once daily). Within each dose cohort, subjects will be stratified approximately 1:1 ratio into 2 age groups: ages 6 to &lt; 9 years and ages 9 to &lt; 12 years.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasma Concentration of Fevipiprant at Steady State (ss), After at Least Four Consecutive Days of Dosing, by Area Under the Curve (AUC0-24h,ss)</measure>
    <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
    <description>Area under the curve (AUC0-24h,ss), steady state following drug administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Plasma Concentration of Fevipiprant at Steady State (ss), After at Least Four Consecutive Days of Dosing, by Cmax,ss</measure>
    <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
    <description>Maximum plasma concentration (Cmax,ss) steady state following drug administration.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Concentration at Steady State (ss), After at Least Four Consecutive Days of Dosing, by Oral Clearance (CL/F)</measure>
    <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
    <description>Oral clearance (CL/F), steady state following drug administration.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Fevipiprant by CL/F</measure>
    <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours.</time_frame>
    <description>Pharmacokinetics of fevipiprant by oral clearance (CL/F) at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Fevipiprant by Tmax,ss</measure>
    <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
    <description>Pharmacokinetics of fevipiprant by time of maximum plasma concentration (Tmax,ss) at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Excretion of Fevipiprant</measure>
    <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours.</time_frame>
    <description>CLr, amount and fraction of dose excreted over the PK collection interval at steady state, of fevipiprant</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of Fevipiprant by Cmin,ss</measure>
    <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
    <description>Pharmacokinetics of fevipiprant by minimum plasma concentration (Cmin,ss) at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of the Metabolite CCN362 by AUC0-24h,ss</measure>
    <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
    <description>Pharmacokinetics of CCN362 metabolite of fevipiprant , area under the curve (AUC0-24h,ss) at steady state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of the Metabolite CCN362 by Cmax,ss</measure>
    <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
    <description>Pharmacokinetics of CCN362 metabolite of fevipiprant by maximum plasma concentration (Cmax,ss) at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of the Metabolite CCN362 by Cmin,ss</measure>
    <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
    <description>Pharmacokinetics of CCN362 metabolite of fevipiprant by minimum plasma concentration (Cmin,ss) at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of the Metabolite CCN362 by Tmax,ss</measure>
    <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
    <description>Pharmacokinetics of CCN362 metabolite of fevipiprant by time of maximum plasma concentration (Tmax,ss) at steady state</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Urinary Excretion of the Metabolite, CCN362</measure>
    <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours.</time_frame>
    <description>CLr, amount and fraction of dose excreted over the PK collection interval at steady state, of the metabolite, CCN362</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Cohort A Fevipiprant 75 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QAW039 75 mg Chewable tablet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort B Feviprant 375 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>QAW039 375 mg Chewable tablet</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fevipiprant</intervention_name>
    <description>Chewable tablet</description>
    <arm_group_label>Cohort A Fevipiprant 75 mg</arm_group_label>
    <arm_group_label>Cohort B Feviprant 375 mg</arm_group_label>
    <other_name>QAW039</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children

          -  Written informed consent by parent(s)/legal guardian(s) for the pediatric patient and
             assent by the pediatric patient (depending on local requirements) must be obtained
             before any study-specific assessment is performed.

          -  Confirmed/documented diagnosis of asthma, as defined by national or international
             asthma guidelines for at least 6 months prior to study enrollment.

          -  Subjects using asthma rescue medication (e.g. SABA) without asthma controller therapy
             or patients receiving daily treatment with a stable dose ICS (with or without
             additional controller such as long-acting β-agonists (LABA), long-acting muscarinic
             antagonists (LAMA)) for at least 4 weeks prior to Treatment Visit (Day 1).

          -  Subjects must be able to attend study visits as per Study Visit Assessment Schedule
             (Section 8) which includes 8 to 9 hours in the clinic/home on the day of End of
             Treatment Visit and have blood draws as scheduled in the study.

        Exclusion Criteria:

          -  Use of other investigational drugs within 5 half-lives of enrollment, or (within 30
             days (for small molecules)/until the expected pharmacodynamic effect has returned to
             baseline (for biologics)), whichever is longer.

          -  Subject is unable to ingest banana and/or yogurt

          -  History of hypersensitivity to any of the study drugs or its excipients or to drugs of
             similar chemical classes.

          -  History of chronic lung disease other than asthma such as and not limited to,
             sarcoidosis interstitial lung disease, cystic fibrosis, mycobacterial or other
             infection (including active tuberculosis or atypical mycobacterial disease).

          -  History of active bacterial, viral or fungal infection within 6 weeks of Treatment
             Visit (Day 1).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55402</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Columbia</city>
        <state>Missouri</state>
        <zip>65203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28277</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Boerne</city>
        <state>Texas</state>
        <zip>78006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>79903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>London</city>
        <zip>SE5 8AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>August 27, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <results_first_submitted>July 1, 2020</results_first_submitted>
  <results_first_submitted_qc>July 1, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">July 20, 2020</results_first_posted>
  <last_update_submitted>July 1, 2020</last_update_submitted>
  <last_update_submitted_qc>July 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 20, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Fevipiprant,</keyword>
  <keyword>GINA 2018,</keyword>
  <keyword>Pediatrics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>February 28, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03650400/SAP_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>February 13, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT03650400/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Six US centers recruited 11 subjects in the study.</recruitment_details>
      <pre_assignment_details>A total of 19 subjects were screened to enroll 11 subjects in the study</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Cohort A Fevipiprant 75 mg</title>
          <description>QAW039 75 mg Chewable tablet</description>
        </group>
        <group group_id="P2">
          <title>Cohort B Feviprant 375 mg</title>
          <description>QAW039 375 mg Chewable tablet</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Study terminated by sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Cohort A Fevipiprant 75 mg</title>
          <description>QAW039 75 mg Chewable tablet</description>
        </group>
        <group group_id="B2">
          <title>Cohort B Feviprant 375 mg</title>
          <description>QAW039 375 mg Chewable tablet</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="11"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8.2" spread="1.83"/>
                    <measurement group_id="B2" value="9.4" spread="1.52"/>
                    <measurement group_id="B3" value="8.7" spread="1.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration of Fevipiprant at Steady State (ss), After at Least Four Consecutive Days of Dosing, by Area Under the Curve (AUC0-24h,ss)</title>
        <description>Area under the curve (AUC0-24h,ss), steady state following drug administration</description>
        <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
        <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Fevipiprant 75 mg</title>
            <description>QAW039 75 mg Chewable tablet</description>
          </group>
          <group group_id="O2">
            <title>Cohort B Feviprant 375 mg</title>
            <description>QAW039 375 mg Chewable tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration of Fevipiprant at Steady State (ss), After at Least Four Consecutive Days of Dosing, by Area Under the Curve (AUC0-24h,ss)</title>
          <description>Area under the curve (AUC0-24h,ss), steady state following drug administration</description>
          <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2380" spread="1880"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Maximum Plasma Concentration of Fevipiprant at Steady State (ss), After at Least Four Consecutive Days of Dosing, by Cmax,ss</title>
        <description>Maximum plasma concentration (Cmax,ss) steady state following drug administration.</description>
        <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
        <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Fevipiprant 75 mg</title>
            <description>QAW039 75 mg Chewable tablet</description>
          </group>
          <group group_id="O2">
            <title>Cohort B Feviprant 375 mg</title>
            <description>QAW039 375 mg Chewable tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration of Fevipiprant at Steady State (ss), After at Least Four Consecutive Days of Dosing, by Cmax,ss</title>
          <description>Maximum plasma concentration (Cmax,ss) steady state following drug administration.</description>
          <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="394" spread="286"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasma Concentration at Steady State (ss), After at Least Four Consecutive Days of Dosing, by Oral Clearance (CL/F)</title>
        <description>Oral clearance (CL/F), steady state following drug administration.</description>
        <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
        <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Fevipiprant 75 mg</title>
            <description>QAW039 75 mg Chewable tablet</description>
          </group>
          <group group_id="O2">
            <title>Cohort B Feviprant 375 mg</title>
            <description>QAW039 375 mg Chewable tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Plasma Concentration at Steady State (ss), After at Least Four Consecutive Days of Dosing, by Oral Clearance (CL/F)</title>
          <description>Oral clearance (CL/F), steady state following drug administration.</description>
          <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" spread="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Fevipiprant by CL/F</title>
        <description>Pharmacokinetics of fevipiprant by oral clearance (CL/F) at steady state</description>
        <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours.</time_frame>
        <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Fevipiprant 75 mg</title>
            <description>QAW039 75 mg Chewable tablet</description>
          </group>
          <group group_id="O2">
            <title>Cohort B Feviprant 375 mg</title>
            <description>QAW039 375 mg Chewable tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Fevipiprant by CL/F</title>
          <description>Pharmacokinetics of fevipiprant by oral clearance (CL/F) at steady state</description>
          <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.2" spread="32.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Fevipiprant by Tmax,ss</title>
        <description>Pharmacokinetics of fevipiprant by time of maximum plasma concentration (Tmax,ss) at steady state</description>
        <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
        <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Fevipiprant 75 mg</title>
            <description>QAW039 75 mg Chewable tablet</description>
          </group>
          <group group_id="O2">
            <title>Cohort B Feviprant 375 mg</title>
            <description>QAW039 375 mg Chewable tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Fevipiprant by Tmax,ss</title>
          <description>Pharmacokinetics of fevipiprant by time of maximum plasma concentration (Tmax,ss) at steady state</description>
          <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="0.916"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Excretion of Fevipiprant</title>
        <description>CLr, amount and fraction of dose excreted over the PK collection interval at steady state, of fevipiprant</description>
        <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours.</time_frame>
        <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Fevipiprant 75 mg</title>
            <description>QAW039 75 mg Chewable tablet</description>
          </group>
          <group group_id="O2">
            <title>Cohort B Feviprant 375 mg</title>
            <description>QAW039 375 mg Chewable tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Excretion of Fevipiprant</title>
          <description>CLr, amount and fraction of dose excreted over the PK collection interval at steady state, of fevipiprant</description>
          <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.61" spread="4.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of Fevipiprant by Cmin,ss</title>
        <description>Pharmacokinetics of fevipiprant by minimum plasma concentration (Cmin,ss) at steady state</description>
        <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
        <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Fevipiprant 75 mg</title>
            <description>QAW039 75 mg Chewable tablet</description>
          </group>
          <group group_id="O2">
            <title>Cohort B Feviprant 375 mg</title>
            <description>QAW039 375 mg Chewable tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of Fevipiprant by Cmin,ss</title>
          <description>Pharmacokinetics of fevipiprant by minimum plasma concentration (Cmin,ss) at steady state</description>
          <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.3" spread="13.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of the Metabolite CCN362 by AUC0-24h,ss</title>
        <description>Pharmacokinetics of CCN362 metabolite of fevipiprant , area under the curve (AUC0-24h,ss) at steady state.</description>
        <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
        <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Fevipiprant 75 mg</title>
            <description>QAW039 75 mg Chewable tablet</description>
          </group>
          <group group_id="O2">
            <title>Cohort B Feviprant 375 mg</title>
            <description>QAW039 375 mg Chewable tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of the Metabolite CCN362 by AUC0-24h,ss</title>
          <description>Pharmacokinetics of CCN362 metabolite of fevipiprant , area under the curve (AUC0-24h,ss) at steady state.</description>
          <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
          <units>h*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2760" spread="1210"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of the Metabolite CCN362 by Cmax,ss</title>
        <description>Pharmacokinetics of CCN362 metabolite of fevipiprant by maximum plasma concentration (Cmax,ss) at steady state</description>
        <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
        <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Fevipiprant 75 mg</title>
            <description>QAW039 75 mg Chewable tablet</description>
          </group>
          <group group_id="O2">
            <title>Cohort B Feviprant 375 mg</title>
            <description>QAW039 375 mg Chewable tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of the Metabolite CCN362 by Cmax,ss</title>
          <description>Pharmacokinetics of CCN362 metabolite of fevipiprant by maximum plasma concentration (Cmax,ss) at steady state</description>
          <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="302" spread="134"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of the Metabolite CCN362 by Cmin,ss</title>
        <description>Pharmacokinetics of CCN362 metabolite of fevipiprant by minimum plasma concentration (Cmin,ss) at steady state</description>
        <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
        <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Fevipiprant 75 mg</title>
            <description>QAW039 75 mg Chewable tablet</description>
          </group>
          <group group_id="O2">
            <title>Cohort B Feviprant 375 mg</title>
            <description>QAW039 375 mg Chewable tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of the Metabolite CCN362 by Cmin,ss</title>
          <description>Pharmacokinetics of CCN362 metabolite of fevipiprant by minimum plasma concentration (Cmin,ss) at steady state</description>
          <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
          <units>ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.6" spread="22.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pharmacokinetics of the Metabolite CCN362 by Tmax,ss</title>
        <description>Pharmacokinetics of CCN362 metabolite of fevipiprant by time of maximum plasma concentration (Tmax,ss) at steady state</description>
        <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours)</time_frame>
        <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Fevipiprant 75 mg</title>
            <description>QAW039 75 mg Chewable tablet</description>
          </group>
          <group group_id="O2">
            <title>Cohort B Feviprant 375 mg</title>
            <description>QAW039 375 mg Chewable tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Pharmacokinetics of the Metabolite CCN362 by Tmax,ss</title>
          <description>Pharmacokinetics of CCN362 metabolite of fevipiprant by time of maximum plasma concentration (Tmax,ss) at steady state</description>
          <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
          <units>h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.69" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Urinary Excretion of the Metabolite, CCN362</title>
        <description>CLr, amount and fraction of dose excreted over the PK collection interval at steady state, of the metabolite, CCN362</description>
        <time_frame>End of Treatment (pre-dose, 0.5hours, 1 hour, 2 hours, 3 hours, 5 hours and 8 hours.</time_frame>
        <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
        <group_list>
          <group group_id="O1">
            <title>Cohort A Fevipiprant 75 mg</title>
            <description>QAW039 75 mg Chewable tablet</description>
          </group>
          <group group_id="O2">
            <title>Cohort B Feviprant 375 mg</title>
            <description>QAW039 375 mg Chewable tablet</description>
          </group>
        </group_list>
        <measure>
          <title>Urinary Excretion of the Metabolite, CCN362</title>
          <description>CLr, amount and fraction of dose excreted over the PK collection interval at steady state, of the metabolite, CCN362</description>
          <population>All treated participants with a valid PK measurement. No PK samples were collected for PK analysis in Cohort B due to early study termination.</population>
          <units>L/h</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.10" spread="1.96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events (AEs) are presented from first dose of study treatment until last dose of study treatment plus 7 days post treatment. Serious AEs are presented from first dose of study treatment until last dose of study treatment plus 30 days post treatment, up to maximum duration of 38 weeks.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Cohort A Fevipiprant 75 mg</title>
          <description>QAW039 75 mg Chewable tablet</description>
        </group>
        <group group_id="E2">
          <title>Cohort B Feviprant 375 mg</title>
          <description>QAW039 375 mg Chewable tablet</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (ie, data from all sites) in the clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Study Director</name_or_title>
      <organization>Novartis Pharmaceuticals</organization>
      <phone>882 778 8300</phone>
      <email>Novartis.email@Novartis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

